Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients
- PMID: 21861666
- PMCID: PMC3225002
- DOI: 10.2217/bmm.11.33
Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients
Abstract
Aims: To investigate associations between novel human cytochrome P450 (CYP450) combinatory (multigene) and substrate-specific drug metabolism indices, and elements of metabolic syndrome, such as low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), triglycerides and BMI, using physiogenomic analysis.
Methods: CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. Data analysis compared clinical measures of LDLc, HDLc, triglyceride and BMI with novel combinatory and substrate-specific CYP450 drug metabolism indices.
Results: We found that a greater metabolic reserve index score is related to lower LDLc and higher HDLc, and that a greater metabolic alteration index score corresponds with higher LDLc and lower HLDc values. We also discovered that the sertraline drug-specific indices correlated with cholesterol and triglyceride values.
Conclusions: Overall, we demonstrated how a multigene approach to CYP450 genotype analysis yields more accurate and significant results than single-gene analyses. Ranking the individual with respect to the population represents a potential tool for assessing risk of dyslipidemia in major depressive disorder patients who are being treated with psychotropics. In addition, the drug-specific indices appear useful for modeling a variable of potential relevance to an individual's risk of drug-related dyslipidemia.
Figures



Similar articles
-
Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.Biomark Med. 2011 Aug;5(4):427-38. doi: 10.2217/bmm.11.32. Biomark Med. 2011. PMID: 21861665 Free PMC article.
-
Applications of CYP450 testing in the clinical setting.Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Mol Diagn Ther. 2013. PMID: 23588782 Free PMC article. Review.
-
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Mol Diagn Ther. 2006;10(3):135-51. doi: 10.1007/BF03256453. Mol Diagn Ther. 2006. PMID: 16771600 Review.
-
Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. doi: 10.1089/cap.2008.0103. J Child Adolesc Psychopharmacol. 2009. PMID: 19702490 Free PMC article.
-
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):385-91. doi: 10.1007/s00406-012-0375-y. Epub 2012 Oct 19. Eur Arch Psychiatry Clin Neurosci. 2013. PMID: 23081704
Cited by
-
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.Biomark Med. 2013 Jun;7(3):429-39. doi: 10.2217/bmm.13.16. Biomark Med. 2013. PMID: 23734807 Free PMC article.
-
Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.Front Pharmacol. 2022 Apr 12;13:884213. doi: 10.3389/fphar.2022.884213. eCollection 2022. Front Pharmacol. 2022. PMID: 35496293 Free PMC article.
-
Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.Biomark Med. 2011 Aug;5(4):427-38. doi: 10.2217/bmm.11.32. Biomark Med. 2011. PMID: 21861665 Free PMC article.
-
The Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION): registry overview and protocol for a propensity score-matched study of opioid prescribing in patients with low back pain.J Pain Res. 2018 Sep 6;11:1751-1760. doi: 10.2147/JPR.S169275. eCollection 2018. J Pain Res. 2018. PMID: 30233232 Free PMC article.
-
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19/CYP2D6 genes play a role? A UK population-based study.J Psychopharmacol. 2023 Apr;37(4):396-407. doi: 10.1177/02698811231152748. Epub 2023 Feb 11. J Psychopharmacol. 2023. PMID: 36772859 Free PMC article.
References
-
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93. - PubMed
-
- Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480–491. - PubMed
-
- Goethe JW, Szarek BL, Woolley SB, Caley CF. Metabolic abnormalities in psychiatric inpatients. Presented at: American Psychiatric Association meeting; San Diego, CA, USA. 19–24 May 2007.
-
- Goethe JW. Metabolic syndrome in psychiatric inpatients receiving antipsychotics. Presented at: American Psychiatric Association meeting; Atlanta, GA, USA. 21–26 May 2005.
-
- Goethe JW, Szarek BL, Caley CF, et al. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry. 2007;68(1):22–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources